# meta::id = AMALGUM_academic_dasatinib
# meta::title = Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets
# meta::shortTitle = dasatinib
# meta::author = Ildik&#243; Beke Debreceni, Gabriella Mezei, P&#233;ter Bat&#225;r, &#193;rp&#225;d Ill&#233;s, J&#225;nos Kappelmayer
# meta::type = academic
# meta::dateCollected = 2019-11-03
# meta::sourceURL = https://www.mdpi.com/1422-0067/20/21/5430/htm
# meta::speakerList = none
# meta::speakerCount = 0
# newdoc id = AMALGUM_academic_dasatinib
# sent_id = AMALGUM_academic_dasatinib-1
# s_type = frag
# text = 1. Introduction
# newpar = head (1 s)
1	1.	1.	X	LS	_	2	dep	2:dep	Discourse=preparation:1->2
2	Introduction	introduction	NOUN	NN	Number=Sing	0	root	0:root	Entity=(abstract-1)

# sent_id = AMALGUM_academic_dasatinib-2
# s_type = decl
# text = Tyrosine kinase inhibitors (TKIs) are widely used drugs as a targeted strategy for cancer treatment with the aim of prolonging progression-free survival.
# newpar = p (16 s)
1	Tyrosine	tyrosine	NOUN	NN	Number=Sing	2	compound	2:compound	Discourse=ROOT:2|Entity=(abstract-2(abstract-3(abstract-4)
2	kinase	kinase	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=abstract-3)
3	inhibitors	inhibitor	NOUN	NNS	Number=Plur	10	nsubj:pass	10:nsubj:pass	Entity=abstract-2)
4	(	(	PUNCT	-LRB-	_	5	punct	5:punct	Discourse=restatement:3->2|SpaceAfter=No
5	TKIs	Tkis	NOUN	NNS	Number=Plur	3	appos	3:appos	Entity=(abstract-2)|SpaceAfter=No
6	)	)	PUNCT	-RRB-	_	5	punct	5:punct	_
7	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	10	aux:pass	10:aux:pass	Discourse=same_unit:4->2
8	widely	widely	ADV	RB	Degree=Pos	9	advmod	9:advmod	Entity=(substance-5
9	used	use	VERB	VBN	Tense=Past|VerbForm=Part	10	amod	10:amod	_
10	drugs	drug	NOUN	NNS	Number=Plur	0	root	0:root	_
11	as	as	ADP	IN	_	14	case	14:case	_
12	a	a	DET	DT	Definite=Ind|PronType=Art	14	det	14:det	Entity=(abstract-6
13	targeted	target	VERB	VBN	Tense=Past|VerbForm=Part	14	amod	14:amod	_
14	strategy	strategy	NOUN	NN	Number=Sing	10	nmod	10:nmod:as	_
15	for	for	ADP	IN	_	17	case	17:case	_
16	cancer	cancer	NOUN	NN	Number=Sing	17	compound	17:compound	Entity=(event-7
17	treatment	treatment	NOUN	NN	Number=Sing	14	nmod	14:nmod:for	Entity=abstract-6)event-7)
18	with	with	ADP	IN	_	20	case	20:case	_
19	the	the	DET	DT	Definite=Def|PronType=Art	20	det	20:det	Entity=(abstract-8
20	aim	aim	NOUN	NN	Number=Sing	10	nmod	10:nmod:with	_
21	of	of	SCONJ	IN	_	22	mark	22:mark	Discourse=elaboration:5->2
22	prolonging	prolong	VERB	VBG	VerbForm=Ger	20	acl	20:acl:of	_
23	progression-free	progression-free	ADJ	JJ	Degree=Pos	24	amod	24:amod	Entity=(event-9
24	survival	survival	NOUN	NN	Number=Sing	22	obj	22:obj	Entity=substance-5)abstract-8)event-9)|SpaceAfter=No
25	.	.	PUNCT	.	_	10	punct	10:punct	_

# sent_id = AMALGUM_academic_dasatinib-3
# s_type = decl
# text = Deregulated tyrosine kinase activity of the BCR-ABL oncoprotein is the biochemical hallmark of Philadelphia chromosome-positive (Ph+) hematological malignancies.
1	Deregulated	Deregulate	VERB	VBN	Tense=Past|VerbForm=Part	4	amod	4:amod	Discourse=elaboration:6->2|Entity=(abstract-10
2	tyrosine	tyrosine	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=(abstract-3(abstract-4)
3	kinase	kinase	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=abstract-3)
4	activity	activity	NOUN	NN	Number=Sing	12	nsubj	12:nsubj	_
5	of	of	ADP	IN	_	8	case	8:case	_
6	the	the	DET	DT	Definite=Def|PronType=Art	8	det	8:det	Entity=(substance-11
7	BCR-ABL	BCR-ABL	PROPN	NNP	Number=Sing	8	compound	8:compound	Entity=(abstract-12)
8	oncoprotein	oncoprotein	NOUN	NN	Number=Sing	4	nmod	4:nmod:of	Entity=abstract-10)substance-11)
9	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	12	cop	12:cop	_
10	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(abstract-10
11	biochemical	biochemical	ADJ	JJ	Degree=Pos	12	amod	12:amod	_
12	hallmark	hallmark	NOUN	NN	Number=Sing	0	root	0:root	_
13	of	of	ADP	IN	_	20	case	20:case	_
14	Philadelphia	Philadelphia	PROPN	NNP	Number=Sing	15	compound	15:compound	Entity=(event-13(abstract-14(person-15)
15	chromosome-positive	chromosome-positive	NOUN	NN	Number=Sing	20	compound	20:compound	Entity=abstract-14)
16	(	(	PUNCT	-LRB-	_	17	punct	17:punct	Discourse=restatement:7->6|SpaceAfter=No
17	Ph+	Ph+	PROPN	NNP	Number=Sing	15	appos	15:appos	Entity=(abstract-14)|SpaceAfter=No
18	)	)	PUNCT	-RRB-	_	17	punct	17:punct	_
19	hematological	hematological	ADJ	JJ	Degree=Pos	20	amod	20:amod	Discourse=same_unit:8->6
20	malignancies	malignancy	NOUN	NNS	Number=Plur	12	nmod	12:nmod:of	Entity=abstract-10)event-13)|SpaceAfter=No
21	.	.	PUNCT	.	_	12	punct	12:punct	_

# sent_id = AMALGUM_academic_dasatinib-4
# s_type = decl
# text = Currently, several generations of BCR-ABL TKIs are in clinical use for treatment of these malignancies.
1	Currently	currently	ADV	RB	Degree=Pos	11	advmod	11:advmod	Discourse=joint:9->2|SpaceAfter=No
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	several	several	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(abstract-16
4	generations	generation	NOUN	NNS	Number=Plur	11	nsubj	11:nsubj	_
5	of	of	ADP	IN	_	7	case	7:case	_
6	BCR-ABL	BCR-ABL	PROPN	NNP	Number=Sing	7	compound	7:compound	Entity=(abstract-2(abstract-12)
7	TKIs	Tkis	NOUN	NNS	Number=Plur	4	nmod	4:nmod:of	Entity=abstract-16)abstract-2)
8	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	11	cop	11:cop	_
9	in	in	ADP	IN	_	11	case	11:case	_
10	clinical	clinical	ADJ	JJ	Degree=Pos	11	amod	11:amod	Entity=(abstract-17
11	use	use	NOUN	NN	Number=Sing	0	root	0:root	_
12	for	for	ADP	IN	_	13	case	13:case	_
13	treatment	treatment	NOUN	NN	Number=Sing	11	nmod	11:nmod:for	Entity=(event-7
14	of	of	ADP	IN	_	16	case	16:case	_
15	these	this	DET	DT	Number=Plur|PronType=Dem	16	det	16:det	Entity=(event-13
16	malignancies	malignancy	NOUN	NNS	Number=Plur	13	nmod	13:nmod:of	Entity=abstract-17)event-7)event-13)|SpaceAfter=No
17	.	.	PUNCT	.	_	11	punct	11:punct	_

# sent_id = AMALGUM_academic_dasatinib-5
# s_type = decl
# text = Introduction of the second-generation TKIs, nilotinib and dasatinib as first-line treatment resulted in rapid and deep reduction of BCR/ABL1 allele transcripts, and this provided a possibility for long-term survival in CML.
1	Introduction	introduction	NOUN	NN	Number=Sing	13	nsubj	13:nsubj	Discourse=joint:10->2|Entity=(abstract-1
2	of	of	ADP	IN	_	5	case	5:case	_
3	the	the	DET	DT	Definite=Def|PronType=Art	5	det	5:det	Entity=(abstract-2(abstract-18
4	second-generation	second-generation	NOUN	NN	Number=Sing	5	compound	5:compound	_
5	TKIs	Tkis	PROPN	NNP	Number=Sing	1	nmod	1:nmod:of	Entity=abstract-18)|SpaceAfter=No
6	,	,	PUNCT	,	_	7	punct	7:punct	_
7	nilotinib	nilotinib	NOUN	NN	Number=Sing	5	conj	1:nmod:of|5:conj:and	Entity=(substance-19)
8	and	and	CCONJ	CC	_	9	cc	9:cc	_
9	dasatinib	dasatinib	NOUN	NN	Number=Sing	5	conj	1:nmod:of|5:conj:and	Entity=abstract-2)(substance-20)
10	as	as	ADP	IN	_	12	case	12:case	_
11	first-line	first-line	ADJ	JJ	Degree=Pos	12	amod	12:amod	Entity=(event-7
12	treatment	treatment	NOUN	NN	Number=Sing	1	nmod	1:nmod:as	Entity=abstract-1)event-7)
13	resulted	result	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	0	root	0:root	_
14	in	in	ADP	IN	_	18	case	18:case	_
15	rapid	rapid	ADJ	JJ	Degree=Pos	18	amod	18:amod	Entity=(event-21
16	and	and	CCONJ	CC	_	17	cc	17:cc	_
17	deep	deep	ADJ	JJ	Degree=Pos	15	conj	15:conj:and|18:amod	_
18	reduction	reduction	NOUN	NN	Number=Sing	13	obl	13:obl:in	_
19	of	of	ADP	IN	_	22	case	22:case	_
20	BCR/ABL1	BCR/ABL1	PROPN	NNP	Number=Sing	22	compound	22:compound	Entity=(abstract-22(abstract-23)
21	allele	allele	NOUN	NN	Number=Sing	22	compound	22:compound	Entity=(object-24)
22	transcripts	transcript	NOUN	NNS	Number=Plur	18	nmod	18:nmod:of	Entity=event-21)abstract-22)|SpaceAfter=No
23	,	,	PUNCT	,	_	26	punct	26:punct	_
24	and	and	CCONJ	CC	_	26	cc	26:cc	Discourse=joint:11->2
25	this	this	PRON	DT	Number=Sing|PronType=Dem	26	nsubj	26:nsubj	Entity=(event-7)
26	provided	provide	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	13	conj	13:conj:and	_
27	a	a	DET	DT	Definite=Ind|PronType=Art	28	det	28:det	Entity=(abstract-25
28	possibility	possibility	NOUN	NN	Number=Sing	26	obj	26:obj	_
29	for	for	ADP	IN	_	31	case	31:case	_
30	long-term	long-term	ADJ	JJ	Degree=Pos	31	amod	31:amod	Entity=(event-9
31	survival	survival	NOUN	NN	Number=Sing	28	nmod	28:nmod:for	_
32	in	in	ADP	IN	_	33	case	33:case	_
33	CML	CML	PROPN	NNP	Number=Sing	31	nmod	31:nmod:in	Entity=abstract-25)event-9)(abstract-26)|SpaceAfter=No
34	.	.	PUNCT	.	_	13	punct	13:punct	_

# sent_id = AMALGUM_academic_dasatinib-6
# s_type = decl
# text = In addition to CML, several other patient populations were identified that undoubtedly benefited from TKI treatment.
1	In	in	ADP	IN	_	2	case	2:case	Discourse=preparation:12->17
2	addition	addition	NOUN	NN	Number=Sing	11	obl	11:obl:in	_
3	to	to	ADP	IN	_	4	case	4:case	_
4	CML	CML	PROPN	NNP	Number=Sing	2	nmod	2:nmod:to	Entity=(abstract-26)|SpaceAfter=No
5	,	,	PUNCT	,	_	2	punct	2:punct	_
6	several	several	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(person-27
7	other	other	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
8	patient	patient	NOUN	NN	Number=Sing	9	compound	9:compound	_
9	populations	population	NOUN	NNS	Number=Plur	11	nsubj:pass	11:nsubj:pass	Entity=person-27)
10	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	11	aux:pass	11:aux:pass	_
11	identified	identify	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root|14:nsubj	_
12	that	that	PRON	WDT	PronType=Rel	14	nsubj	11:ref	Discourse=elaboration:13->12
13	undoubtedly	undoubtedly	ADV	RB	Degree=Pos|Polarity=Neg	14	advmod	14:advmod	_
14	benefited	benefit	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	11	acl:relcl	11:acl:relcl	_
15	from	from	ADP	IN	_	17	case	17:case	_
16	TKI	TKI	PROPN	NNP	Number=Sing	17	compound	17:compound	Entity=(event-7(abstract-28)
17	treatment	treatment	NOUN	NN	Number=Sing	14	obl	14:obl:from	Entity=event-7)|SpaceAfter=No
18	.	.	PUNCT	.	_	11	punct	11:punct	_

# sent_id = AMALGUM_academic_dasatinib-7
# s_type = decl
# text = Patients with Ph+ adult acute lymphoblastic leukemia (ALL) may also benefit from an alternate TKI therapy.
1	Patients	patient	NOUN	NNS	Number=Plur	13	nsubj	13:nsubj	Discourse=preparation:14->17|Entity=(person-29
2	with	with	ADP	IN	_	7	case	7:case	_
3	Ph+	Ph+	PROPN	NNP	Number=Sing	7	compound	7:compound	Entity=(abstract-30(abstract-14)
4	adult	adult	NOUN	NN	Number=Sing	7	compound	7:compound	_
5	acute	acute	ADJ	JJ	Degree=Pos	7	amod	7:amod	_
6	lymphoblastic	lymphoblastic	ADJ	JJ	Degree=Pos	7	amod	7:amod	_
7	leukemia	leukemia	NOUN	NN	Number=Sing	1	nmod	1:nmod:with	Entity=person-29)abstract-30)
8	(	(	PUNCT	-LRB-	_	9	punct	9:punct	Discourse=elaboration:15->14|SpaceAfter=No
9	ALL	ALL	PROPN	NNP	Number=Sing	7	appos	7:appos	Entity=(abstract-30)|SpaceAfter=No
10	)	)	PUNCT	-RRB-	_	9	punct	9:punct	_
11	may	may	AUX	MD	VerbForm=Fin	13	aux	13:aux	Discourse=same_unit:16->14
12	also	also	ADV	RB	_	13	advmod	13:advmod	_
13	benefit	benefit	VERB	VB	VerbForm=Inf	0	root	0:root	_
14	from	from	ADP	IN	_	18	case	18:case	_
15	an	a	DET	DT	Definite=Ind|PronType=Art	18	det	18:det	Entity=(abstract-31
16	alternate	alternate	ADJ	JJ	Degree=Pos	18	amod	18:amod	_
17	TKI	TKI	PROPN	NNP	Number=Sing	18	compound	18:compound	Entity=(abstract-28)
18	therapy	therapy	NOUN	NN	Number=Sing	13	obl	13:obl:from	Entity=abstract-31)|SpaceAfter=No
19	.	.	PUNCT	.	_	13	punct	13:punct	_

# sent_id = AMALGUM_academic_dasatinib-8
# s_type = frag
# text = In the treatment of pediatric patients with Ph+ ALL
1	In	in	ADP	IN	_	3	case	3:case	Discourse=joint:17->2
2	the	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	Entity=(abstract-32
3	treatment	treatment	NOUN	NN	Number=Sing	9	obl:npmod	9:obl:npmod	_
4	of	of	ADP	IN	_	6	case	6:case	_
5	pediatric	pediatric	ADJ	JJ	Degree=Pos	6	amod	6:amod	Entity=(person-29
6	patients	patient	NOUN	NNS	Number=Plur	3	nmod	3:nmod:of	_
7	with	with	ADP	IN	_	8	case	8:case	_
8	Ph+	Ph+	PROPN	NNP	Number=Sing	6	nmod	6:nmod:with	Entity=abstract-32)person-29)(abstract-14)
9	ALL	ALL	NOUN	NN	Number=Sing	0	root	0:root	Entity=(person-33)

# sent_id = AMALGUM_academic_dasatinib-9
# s_type = decl
# text = the addition of TKIs to conventional chemotherapy has improved outcomes of patients.
1	the	the	DET	DT	Definite=Def|PronType=Art	2	det	2:det	Discourse=elaboration:18->17|Entity=(event-34
2	addition	addition	NOUN	NN	Number=Sing	9	nsubj	9:nsubj	_
3	of	of	ADP	IN	_	4	case	4:case	_
4	TKIs	Tkis	NOUN	NN	Number=Sing	2	nmod	2:nmod:of	Entity=(abstract-18)
5	to	to	ADP	IN	_	7	case	7:case	_
6	conventional	conventional	ADJ	JJ	Degree=Pos	7	amod	7:amod	Entity=(substance-35
7	chemotherapy	chemotherapy	NOUN	NN	Number=Sing	2	nmod	2:nmod:to	Entity=event-34)substance-35)
8	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	9	aux	9:aux	_
9	improved	improve	VERB	VBN	Tense=Past|VerbForm=Part	0	root	0:root	_
10	outcomes	outcome	NOUN	NNS	Number=Plur	9	obj	9:obj	Entity=(abstract-36
11	of	of	ADP	IN	_	12	case	12:case	_
12	patients	patient	NOUN	NNS	Number=Plur	10	nmod	10:nmod:of	Entity=abstract-36)(person-29)|SpaceAfter=No
13	.	.	PUNCT	.	_	9	punct	9:punct	_

# sent_id = AMALGUM_academic_dasatinib-10
# s_type = decl
# text = It has long been known that second-generation TKIs may have side effects as nilotinib can potentiate a prothrombotic state while dasatinib is known to cause platelet dysfunction e.g. impaired collagen-induced platelet adhesion and aggregation.
1	It	it	PRON	PRP	Case=Acc|Gender=Neut|Number=Sing|Person=3|PronType=Prs	5	expl	5:expl	Discourse=attribution:19->20|Entity=(abstract-18)
2	has	have	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	5	aux	5:aux	_
3	long	long	ADV	RB	Degree=Pos	5	advmod	5:advmod	_
4	been	be	AUX	VBN	Tense=Past|VerbForm=Part	5	aux:pass	5:aux:pass	_
5	known	know	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
6	that	that	SCONJ	IN	_	10	mark	10:mark	Discourse=joint:20->17
7	second-generation	second-generation	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(abstract-2
8	TKIs	Tkis	NOUN	NNS	Number=Plur	10	nsubj	10:nsubj	Entity=abstract-2)
9	may	may	AUX	MD	VerbForm=Fin	10	aux	10:aux	_
10	have	have	VERB	VB	VerbForm=Inf	5	csubj:pass	5:csubj:pass	_
11	side	side	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-37
12	effects	effect	NOUN	NNS	Number=Plur	10	obj	10:obj	Entity=abstract-37)
13	as	as	SCONJ	IN	_	16	mark	16:mark	Discourse=circumstance:21->20
14	nilotinib	nilotinib	NOUN	NN	Number=Sing	16	nsubj	16:nsubj	Entity=(substance-19)
15	can	can	AUX	MD	VerbForm=Fin	16	aux	16:aux	_
16	potentiate	potentiate	VERB	VB	VerbForm=Inf	10	advcl	10:advcl:as	_
17	a	a	DET	DT	Definite=Ind|PronType=Art	19	det	19:det	Entity=(abstract-38
18	prothrombotic	prothrombotic	ADJ	JJ	Degree=Pos	19	amod	19:amod	_
19	state	state	NOUN	NN	Number=Sing	16	obj	16:obj	Entity=abstract-38)
20	while	while	SCONJ	IN	_	23	mark	23:mark	Discourse=concession:22->23
21	dasatinib	dasatinib	NOUN	NN	Number=Sing	23	nsubj:pass	23:nsubj:pass|25:nsubj:xsubj	Entity=(substance-20)
22	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	23	aux:pass	23:aux:pass	_
23	known	know	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	10	advcl	10:advcl:while	_
24	to	to	PART	TO	_	25	mark	25:mark	_
25	cause	cause	VERB	VB	VerbForm=Inf	23	xcomp	23:xcomp	_
26	platelet	platelet	NOUN	NN	Number=Sing	27	compound	27:compound	Entity=(abstract-39(object-40)
27	dysfunction	dysfunction	NOUN	NN	Number=Sing	25	obj	25:obj	Entity=abstract-39)
28	e.g.	e.g.	ADV	RB	Abbr=Yes|Degree=Pos	29	advmod	29:advmod	Discourse=elaboration:23->21|Entity=(abstract-39(abstract-39
29	impaired	impaired	ADJ	JJ	Degree=Pos	32	amod	32:amod	_
30	collagen-induced	collagen-induced	ADJ	JJ	Degree=Pos	32	amod	32:amod	_
31	platelet	platelet	NOUN	NN	Number=Sing	32	compound	32:compound	Entity=(object-40)
32	adhesion	adhesion	NOUN	NN	Number=Sing	27	appos	27:appos	Entity=abstract-39)
33	and	and	CCONJ	CC	_	34	cc	34:cc	_
34	aggregation	aggregation	NOUN	NN	Number=Sing	32	conj	27:appos|32:conj:and	Entity=abstract-39)(abstract-39)|SpaceAfter=No
35	.	.	PUNCT	.	_	5	punct	5:punct	_

# sent_id = AMALGUM_academic_dasatinib-11
# s_type = decl
# text = Although both drugs bind to the ATP binding site of the kinase domain of the BCR/ABL protein
1	Although	although	SCONJ	IN	_	4	mark	4:mark	Discourse=joint:24->17
2	both	both	DET	DT	_	3	det	3:det	Entity=(substance-5
3	drugs	drug	NOUN	NNS	Number=Plur	4	nsubj	4:nsubj	Entity=substance-5)
4	bind	bind	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	Entity=(event-41)
5	to	to	ADP	IN	_	9	case	9:case	_
6	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(place-42
7	ATP	ATP	PROPN	NNP	Number=Sing	9	compound	9:compound	Entity=(abstract-43)
8	binding	bind	VERB	VBG	VerbForm=Ger	9	amod	9:amod	_
9	site	site	NOUN	NN	Number=Sing	4	obl	4:obl:to	_
10	of	of	ADP	IN	_	13	case	13:case	_
11	the	the	DET	DT	Definite=Def|PronType=Art	13	det	13:det	Entity=(abstract-44
12	kinase	kinase	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(abstract-3)
13	domain	domain	NOUN	NN	Number=Sing	9	nmod	9:nmod:of	_
14	of	of	ADP	IN	_	17	case	17:case	_
15	the	the	DET	DT	Definite=Def|PronType=Art	17	det	17:det	Entity=(substance-45
16	BCR/ABL	BCR/ABL	PROPN	NNP	Number=Sing	17	compound	17:compound	Entity=(organization-46)
17	protein	protein	NOUN	NN	Number=Sing	13	nmod	13:nmod:of	Entity=place-42)abstract-44)substance-45)

# sent_id = AMALGUM_academic_dasatinib-12
# s_type = decl
# text = they have different off target inhibitory effect on several other tyrosine kinases.
1	they	they	PRON	PRP	Case=Nom|Number=Plur|Person=3|PronType=Prs	2	nsubj	2:nsubj	Discourse=elaboration:25->24|Entity=(substance-5)
2	have	have	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
3	different	different	ADJ	JJ	Degree=Pos	7	amod	7:amod	Entity=(abstract-47
4	off	off	ADJ	JJ	Degree=Pos	5	advmod	5:advmod	Entity=(abstract-48
5	target	target	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=abstract-48)
6	inhibitory	inhibitory	ADJ	JJ	Degree=Pos	7	amod	7:amod	_
7	effect	effect	NOUN	NN	Number=Sing	2	obj	2:obj	_
8	on	on	ADP	IN	_	12	case	12:case	_
9	several	several	ADJ	JJ	Degree=Pos	12	amod	12:amod	Entity=(abstract-49
10	other	other	ADJ	JJ	Degree=Pos	12	amod	12:amod	_
11	tyrosine	tyrosine	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-4)
12	kinases	kinase	NOUN	NNS	Number=Plur	7	nmod	7:nmod:on	Entity=abstract-47)abstract-49)|SpaceAfter=No
13	.	.	PUNCT	.	_	2	punct	2:punct	_

# sent_id = AMALGUM_academic_dasatinib-13
# s_type = decl
# text = Dasatinib is a potent multikinase inhibitor, including c-KIT, EPHA2, platelet-derived growth factor receptor-β, and SFKs.
1	Dasatinib	Dasatinib	PROPN	NNP	Number=Sing	6	nsubj	6:nsubj	Discourse=joint:26->17|Entity=(substance-20)
2	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	6	cop	6:cop	_
3	a	a	DET	DT	Definite=Ind|PronType=Art	6	det	6:det	Entity=(substance-20
4	potent	potent	ADJ	JJ	Degree=Pos	6	amod	6:amod	_
5	multikinase	multikinase	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=(abstract-50)
6	inhibitor	inhibitor	NOUN	NN	Number=Sing	0	root	0:root	SpaceAfter=No
7	,	,	PUNCT	,	_	9	punct	9:punct	_
8	including	include	VERB	VBG	VerbForm=Ger	9	case	9:case	Discourse=elaboration:27->26
9	c-KIT	c-KIT	NOUN	NN	Number=Sing	6	nmod	6:nmod:including	Entity=(substance-51)|SpaceAfter=No
10	,	,	PUNCT	,	_	11	punct	11:punct	_
11	EPHA2	EPHA2	PROPN	NNP	Number=Sing	9	conj	6:nmod:including|9:conj:and	Entity=(abstract-52)|SpaceAfter=No
12	,	,	PUNCT	,	_	16	punct	16:punct	_
13	platelet-derived	platelet-derived	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(abstract-53(abstract-54(abstract-55)
14	growth	growth	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(abstract-56)
15	factor	factor	NOUN	NN	Number=Sing	16	compound	16:compound	Entity=abstract-54)
16	receptor-β	receptor-β	NOUN	NN	Number=Sing	9	conj	6:nmod:including|9:conj:and	Entity=abstract-53)|SpaceAfter=No
17	,	,	PUNCT	,	_	19	punct	19:punct	_
18	and	and	CCONJ	CC	_	19	cc	19:cc	_
19	SFKs	SFK	PROPN	NNP	Number=Sing	9	conj	6:nmod:including|9:conj:and	Entity=substance-20)(abstract-57)|SpaceAfter=No
20	.	.	PUNCT	.	_	6	punct	6:punct	_

# sent_id = AMALGUM_academic_dasatinib-14
# s_type = decl
# text = Nilotinib is also a second generation TKI with a broad inhibitory spectrum of various tyrosine kinases (PDGFR, c-KIT, ARG, EPHB4), but it does not inhibit SFKs.
1	Nilotinib	Nilotinib	PROPN	NNP	Number=Sing	7	nsubj	7:nsubj	Discourse=concession:28->30|Entity=(substance-19)
2	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	7	cop	7:cop	_
3	also	also	ADV	RB	_	7	advmod	7:advmod	_
4	a	a	DET	DT	Definite=Ind|PronType=Art	7	det	7:det	Entity=(substance-19
5	second	second	ADJ	JJ	Degree=Pos|NumType=Ord	7	amod	7:amod	_
6	generation	generation	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=(abstract-58)
7	TKI	TKI	PROPN	NNP	Number=Sing	0	root	0:root	_
8	with	with	ADP	IN	_	12	case	12:case	_
9	a	a	DET	DT	Definite=Ind|PronType=Art	12	det	12:det	Entity=(abstract-59
10	broad	broad	ADJ	JJ	Degree=Pos	12	amod	12:amod	_
11	inhibitory	inhibitory	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-60)
12	spectrum	spectrum	NOUN	NN	Number=Sing	7	nmod	7:nmod:with	_
13	of	of	ADP	IN	_	16	case	16:case	_
14	various	various	ADJ	JJ	Degree=Pos	16	amod	16:amod	Entity=(abstract-49
15	tyrosine	tyrosine	NOUN	NN	Number=Sing	16	compound	16:compound	Entity=(abstract-4)
16	kinases	kinase	NOUN	NNS	Number=Plur	12	nmod	12:nmod:of	Entity=substance-19)abstract-59)abstract-49)
17	(	(	PUNCT	-LRB-	_	18	punct	18:punct	Discourse=elaboration:29->28|SpaceAfter=No
18	PDGFR	PDGFR	PROPN	NNP	Number=Sing	16	appos	16:appos	Entity=(abstract-49(abstract-49)|SpaceAfter=No
19	,	,	PUNCT	,	_	20	punct	20:punct	_
20	c-KIT	c-KIT	PROPN	NNP	Number=Sing	18	conj	16:appos|18:conj	Entity=(abstract-49)|SpaceAfter=No
21	,	,	PUNCT	,	_	22	punct	22:punct	_
22	ARG	ARG	PROPN	NNP	Number=Sing	18	conj	16:appos|18:conj	Entity=(abstract-49)|SpaceAfter=No
23	,	,	PUNCT	,	_	24	punct	24:punct	_
24	EPHB4	EphB4	PROPN	NNP	Number=Sing	18	conj	16:appos|18:conj	Entity=abstract-49)(abstract-49)|SpaceAfter=No
25	)	)	PUNCT	-RRB-	_	18	punct	18:punct	SpaceAfter=No
26	,	,	PUNCT	,	_	31	punct	31:punct	_
27	but	but	CCONJ	CC	_	31	cc	31:cc	Discourse=joint:30->17
28	it	it	PRON	PRP	Case=Nom|Gender=Neut|Number=Sing|Person=3|PronType=Prs	31	nsubj	31:nsubj	Entity=(abstract-59)
29	does	do	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	31	aux	31:aux	_
30	not	not	ADV	RB	Polarity=Neg	31	advmod	31:advmod	_
31	inhibit	inhibit	VERB	VB	VerbForm=Inf	7	conj	7:conj:but	_
32	SFKs	SFK	NOUN	NNS	Number=Plur	31	obj	31:obj	Entity=(abstract-57)|SpaceAfter=No
33	.	.	PUNCT	.	_	7	punct	7:punct	_

# sent_id = AMALGUM_academic_dasatinib-15
# s_type = decl
# text = Previous in vitro and ex vivo studies with dasatinib have demonstrated a faulty platelet aggregation.
1	Previous	previous	ADJ	JJ	Degree=Pos	7	amod	7:amod	Discourse=joint:31->17|Entity=(abstract-61
2	in	in	ADP	IN	_	3	case	3:case	_
3	vitro	vitro	NOUN	NN	Number=Sing	7	compound	7:compound	Entity=(abstract-62)
4	and	and	CCONJ	CC	_	6	cc	6:cc	_
5	ex	ex	NOUN	NN	Number=Sing	6	compound	6:compound	Entity=(abstract-63
6	vivo	vivo	NOUN	NN	Number=Sing	3	conj	3:conj:and|7:compound	Entity=abstract-63)
7	studies	study	NOUN	NNS	Number=Plur	11	nsubj	11:nsubj	_
8	with	with	ADP	IN	_	9	case	9:case	_
9	dasatinib	dasatinib	NOUN	NN	Number=Sing	7	nmod	7:nmod:with	Entity=abstract-61)(substance-20)
10	have	have	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	11	aux	11:aux	_
11	demonstrated	demonstrate	VERB	VBN	Tense=Past|VerbForm=Part	0	root	0:root	_
12	a	a	DET	DT	Definite=Ind|PronType=Art	15	det	15:det	Entity=(abstract-64
13	faulty	faulty	ADJ	JJ	Degree=Pos	15	amod	15:amod	_
14	platelet	platelet	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(object-40)
15	aggregation	aggregation	NOUN	NN	Number=Sing	11	obj	11:obj	Entity=abstract-64)|SpaceAfter=No
16	.	.	PUNCT	.	_	11	punct	11:punct	_

# sent_id = AMALGUM_academic_dasatinib-16
# s_type = decl
# text = On the contrary nilotinib has no effect on platelet aggregation, at all.
1	On	on	ADP	IN	_	3	case	3:case	Discourse=joint:32->17
2	the	the	DET	DT	Definite=Def|PronType=Art	3	det	3:det	_
3	contrary	contrary	ADJ	JJ	Degree=Pos	5	obl	5:obl:on	_
4	nilotinib	nilotinib	NOUN	NN	Number=Sing	5	nsubj	5:nsubj	Entity=(substance-19)
5	has	have	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
6	no	no	DET	DT	Polarity=Neg	7	det	7:det	Entity=(abstract-47
7	effect	effect	NOUN	NN	Number=Sing	5	obj	5:obj	_
8	on	on	ADP	IN	_	10	case	10:case	_
9	platelet	platelet	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(abstract-64(object-40)
10	aggregation	aggregation	NOUN	NN	Number=Sing	7	nmod	7:nmod:on	Entity=abstract-47)abstract-64)|SpaceAfter=No
11	,	,	PUNCT	,	_	13	punct	13:punct	_
12	at	at	ADP	IN	_	13	case	13:case	_
13	all	all	PRON	DT	_	5	obl	5:obl:at	Entity=(abstract-64)|SpaceAfter=No
14	.	.	PUNCT	.	_	5	punct	5:punct	_

# sent_id = AMALGUM_academic_dasatinib-17
# s_type = decl
# text = Therefore, we used nilotinib as a negative control in our experiments.
1	Therefore	therefore	ADV	RB	Degree=Pos	4	advmod	4:advmod	Discourse=joint:33->17|SpaceAfter=No
2	,	,	PUNCT	,	_	1	punct	1:punct	_
3	we	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	4	nsubj	4:nsubj	Entity=(person-65)
4	used	use	VERB	VBD	Mood=Ind|Number=Plur|Person=1|Tense=Past|VerbForm=Fin	0	root	0:root	_
5	nilotinib	nilotinib	NOUN	NN	Number=Sing	4	obj	4:obj	Entity=(substance-19)
6	as	as	ADP	IN	_	9	case	9:case	_
7	a	a	DET	DT	Definite=Ind|PronType=Art	9	det	9:det	Entity=(abstract-66
8	negative	negative	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	control	control	NOUN	NN	Number=Sing	4	obl	4:obl:as	Entity=abstract-66)
10	in	in	ADP	IN	_	12	case	12:case	_
11	our	our	PRON	PRP$	Number=Plur|Person=1|Poss=Yes|PronType=Prs	12	nmod:poss	12:nmod:poss	Entity=(event-67(person-65)
12	experiments	experiment	NOUN	NNS	Number=Plur	4	obl	4:obl:in	Entity=event-67)|SpaceAfter=No
13	.	.	PUNCT	.	_	4	punct	4:punct	_

# sent_id = AMALGUM_academic_dasatinib-18
# s_type = decl
# text = Sarcoma family kinases (SFKs) are critical regulators of platelet signaling and activation.
# newpar = p (11 s)
1	Sarcoma	Sarcoma	PROPN	NNP	Number=Sing	2	compound	2:compound	Discourse=joint:34->17|Entity=(abstract-49(person-68(abstract-69)
2	family	family	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=person-68)
3	kinases	kinase	NOUN	NNS	Number=Plur	9	nsubj	9:nsubj	Entity=abstract-49)
4	(	(	PUNCT	-LRB-	_	5	punct	5:punct	Discourse=elaboration:35->34|SpaceAfter=No
5	SFKs	SFK	NOUN	NNS	Number=Plur	3	appos	3:appos	Entity=(abstract-49)|SpaceAfter=No
6	)	)	PUNCT	-RRB-	_	5	punct	5:punct	_
7	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	9	cop	9:cop	Discourse=same_unit:36->34
8	critical	critical	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(abstract-49
9	regulators	regulator	NOUN	NNS	Number=Plur	0	root	0:root	_
10	of	of	ADP	IN	_	12	case	12:case	_
11	platelet	platelet	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-70(object-40)
12	signaling	signaling	NOUN	NN	Number=Sing	9	nmod	9:nmod:of	Entity=abstract-70)
13	and	and	CCONJ	CC	_	14	cc	14:cc	_
14	activation	activation	NOUN	NN	Number=Sing	12	conj	9:nmod:of|12:conj:and	Entity=abstract-49)(event-71)|SpaceAfter=No
15	.	.	PUNCT	.	_	9	punct	9:punct	_

# sent_id = AMALGUM_academic_dasatinib-19
# s_type = decl
# text = These kinases play a central role in mediating rapid response of platelets to vascular injury.
1	These	this	DET	DT	Number=Plur|PronType=Dem	2	det	2:det	Discourse=joint:37->17|Entity=(abstract-49
2	kinases	kinase	NOUN	NNS	Number=Plur	3	nsubj	3:nsubj	Entity=abstract-49)
3	play	play	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
4	a	a	DET	DT	Definite=Ind|PronType=Art	6	det	6:det	Entity=(abstract-72
5	central	central	ADJ	JJ	Degree=Pos	6	amod	6:amod	_
6	role	role	NOUN	NN	Number=Sing	3	obj	3:obj	Entity=abstract-72)
7	in	in	SCONJ	IN	_	8	mark	8:mark	Discourse=elaboration:38->37
8	mediating	mediate	VERB	VBG	VerbForm=Ger	3	advcl	3:advcl:in	_
9	rapid	rapid	ADJ	JJ	Degree=Pos	10	amod	10:amod	Entity=(event-73
10	response	response	NOUN	NN	Number=Sing	8	obj	8:obj	_
11	of	of	ADP	IN	_	12	case	12:case	_
12	platelets	platelet	NOUN	NNS	Number=Plur	10	nmod	10:nmod:of	Entity=(substance-74)
13	to	to	ADP	IN	_	15	case	15:case	_
14	vascular	vascular	ADJ	JJ	Degree=Pos	15	amod	15:amod	Entity=(event-75
15	injury	injury	NOUN	NN	Number=Sing	10	nmod	10:nmod:to	Entity=event-73)event-75)|SpaceAfter=No
16	.	.	PUNCT	.	_	3	punct	3:punct	_

# sent_id = AMALGUM_academic_dasatinib-20
# s_type = decl
# text = They transmit activation signals from several various platelet receptors.
1	They	they	PRON	PRP	Case=Nom|Number=Plur|Person=3|PronType=Prs	2	nsubj	2:nsubj	Discourse=joint:39->17|Entity=(substance-74)
2	transmit	transmit	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
3	activation	activation	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=(abstract-76(event-71)
4	signals	signal	NOUN	NNS	Number=Plur	2	obj	2:obj	_
5	from	from	ADP	IN	_	9	case	9:case	_
6	several	several	ADJ	JJ	Degree=Pos	9	amod	9:amod	Entity=(substance-77
7	various	various	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
8	platelet	platelet	NOUN	NN	Number=Sing	9	compound	9:compound	Entity=(object-40)
9	receptors	receptor	NOUN	NNS	Number=Plur	4	nmod	4:nmod:from	Entity=abstract-76)substance-77)|SpaceAfter=No
10	.	.	PUNCT	.	_	2	punct	2:punct	_

# sent_id = AMALGUM_academic_dasatinib-21
# s_type = decl
# text = There are numerous members of this group and among the SFKs Lyn, Fyn, and Src have been implicated in activation of the GPVI receptor and the integrin receptor signaling and are frequently studied proteins as they are present in both human and mouse platelets.
1	There	there	PRON	EX	_	2	expl	2:expl	Discourse=joint:40->17
2	are	be	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
3	numerous	numerous	ADJ	JJ	Degree=Pos	4	amod	4:amod	Entity=(person-78
4	members	member	NOUN	NNS	Number=Plur	2	nsubj	2:nsubj	_
5	of	of	ADP	IN	_	7	case	7:case	_
6	this	this	DET	DT	Number=Sing|PronType=Dem	7	det	7:det	Entity=(animal-79
7	group	group	NOUN	NN	Number=Sing	4	nmod	4:nmod:of	Entity=person-78)animal-79)
8	and	and	CCONJ	CC	_	20	cc	20:cc	Discourse=elaboration:41->40
9	among	among	ADP	IN	_	11	case	11:case	_
10	the	the	DET	DT	Definite=Def|PronType=Art	11	det	11:det	Entity=(abstract-49
11	SFKs	SFK	PROPN	NNPS	Number=Plur	20	obl	20:obl:among	Entity=abstract-49)
12	Lyn	Lyn	PROPN	NNP	Number=Sing	20	nsubj:pass	20:nsubj:pass|35:nsubj:pass	Entity=(person-80)|SpaceAfter=No
13	,	,	PUNCT	,	_	14	punct	14:punct	_
14	Fyn	Fyn	PROPN	NNP	Number=Sing	12	conj	12:conj:and|20:nsubj:pass	Entity=(abstract-81)|SpaceAfter=No
15	,	,	PUNCT	,	_	17	punct	17:punct	_
16	and	and	CCONJ	CC	_	17	cc	17:cc	_
17	Src	Src	PROPN	NNP	Number=Sing	12	conj	12:conj:and|20:nsubj:pass	Entity=(abstract-82)
18	have	have	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	20	aux	20:aux	_
19	been	be	AUX	VBN	Tense=Past|VerbForm=Part	20	aux:pass	20:aux:pass	_
20	implicated	implicate	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	2	conj	2:conj:and	_
21	in	in	ADP	IN	_	22	case	22:case	_
22	activation	activation	NOUN	NN	Number=Sing	20	obl	20:obl:in	Entity=(event-71
23	of	of	ADP	IN	_	26	case	26:case	_
24	the	the	DET	DT	Definite=Def|PronType=Art	26	det	26:det	Entity=(abstract-83
25	GPVI	GPVI	PROPN	NNP	Number=Sing	26	compound	26:compound	Entity=(abstract-84)
26	receptor	receptor	NOUN	NN	Number=Sing	22	nmod	22:nmod:of	Entity=abstract-83)
27	and	and	CCONJ	CC	_	31	cc	31:cc	_
28	the	the	DET	DT	Definite=Def|PronType=Art	31	det	31:det	Entity=(abstract-70
29	integrin	integrin	NOUN	NN	Number=Sing	30	compound	30:compound	Entity=(abstract-83(person-85)
30	receptor	receptor	NOUN	NN	Number=Sing	31	compound	31:compound	Entity=abstract-83)
31	signaling	signaling	NOUN	NN	Number=Sing	26	conj	22:nmod:of|26:conj:and	Entity=event-71)abstract-70)
32	and	and	CCONJ	CC	_	35	cc	35:cc	Discourse=joint:42->41
33	are	be	AUX	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	35	aux:pass	35:aux:pass	_
34	frequently	frequently	ADV	RB	Degree=Pos	35	advmod	35:advmod	_
35	studied	study	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	20	conj	2:conj|20:conj:and	_
36	proteins	protein	NOUN	NNS	Number=Plur	35	obj	35:obj	Entity=(substance-86)
37	as	as	SCONJ	IN	_	40	mark	40:mark	Discourse=circumstance:43->42
38	they	they	PRON	PRP	Case=Nom|Number=Plur|Person=3|PronType=Prs	40	nsubj	40:nsubj	Entity=(person-78)
39	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	40	cop	40:cop	_
40	present	present	ADJ	JJ	Degree=Pos	35	advcl	35:advcl:as	_
41	in	in	ADP	IN	_	46	case	46:case	_
42	both	both	CCONJ	CC	_	46	det:predet	46:det:predet	Entity=(substance-74
43	human	human	ADJ	JJ	Degree=Pos	46	amod	46:amod	_
44	and	and	CCONJ	CC	_	45	cc	45:cc	_
45	mouse	mouse	NOUN	NN	Number=Sing	43	conj	43:conj:and|46:compound	_
46	platelets	platelet	NOUN	NNS	Number=Plur	40	obl	40:obl:in	Entity=substance-74)|SpaceAfter=No
47	.	.	PUNCT	.	_	2	punct	2:punct	_

# sent_id = AMALGUM_academic_dasatinib-22
# s_type = decl
# text = TKIs have a different off-target multikinase inhibitory effect.
1	TKIs	Tkis	PROPN	NNPS	Number=Plur	2	nsubj	2:nsubj	Discourse=elaboration:44->40|Entity=(abstract-2)
2	have	have	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
3	a	a	DET	DT	Definite=Ind|PronType=Art	8	det	8:det	Entity=(abstract-47
4	different	different	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
5	off-target	off-target	ADJ	JJ	Degree=Pos	8	amod	8:amod	_
6	multikinase	multikinase	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(abstract-50)
7	inhibitory	inhibitory	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(abstract-60)
8	effect	effect	NOUN	NN	Number=Sing	2	obj	2:obj	Entity=abstract-47)|SpaceAfter=No
9	.	.	PUNCT	.	_	2	punct	2:punct	_

# sent_id = AMALGUM_academic_dasatinib-23
# s_type = decl
# text = Comprehensive drug-protein interaction profiles were described to predict the potential side effects of BCR-ABL TKIs.
1	Comprehensive	Comprehensive	ADJ	JJ	Degree=Pos	4	amod	4:amod	Discourse=joint:45->17|Entity=(abstract-87
2	drug-protein	drug-protein	ADJ	JJ	Degree=Pos	3	amod	3:amod	Entity=(abstract-88
3	interaction	interaction	NOUN	NN	Number=Sing	4	compound	4:compound	Entity=abstract-88)
4	profiles	profile	NOUN	NNS	Number=Plur	6	nsubj:pass	6:nsubj:pass|8:nsubj:xsubj	Entity=abstract-87)
5	were	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	6	aux:pass	6:aux:pass	_
6	described	describe	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
7	to	to	PART	TO	_	8	mark	8:mark	Discourse=purpose:46->45
8	predict	predict	VERB	VB	VerbForm=Inf	6	xcomp	6:xcomp	_
9	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(abstract-37
10	potential	potential	ADJ	JJ	Degree=Pos	12	amod	12:amod	_
11	side	side	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(abstract-89)
12	effects	effect	NOUN	NNS	Number=Plur	8	obj	8:obj	_
13	of	of	ADP	IN	_	15	case	15:case	_
14	BCR-ABL	BCR-ABL	PROPN	NNP	Number=Sing	15	compound	15:compound	Entity=(abstract-18(abstract-12)
15	TKIs	Tkis	PROPN	NNP	Number=Sing	12	nmod	12:nmod:of	Entity=abstract-37)abstract-18)|SpaceAfter=No
16	.	.	PUNCT	.	_	6	punct	6:punct	_

# sent_id = AMALGUM_academic_dasatinib-24
# s_type = decl
# text = It was found that the most prominent dasatinib-targeted SFKs are Lyn, Fyn, and Src, kinases and their negative regulator C-terminal Src kinase (Csk), but nilotinib does not bind to these kinases.
1	It	it	PRON	PRP	Case=Acc|Gender=Neut|Number=Sing|Person=3|PronType=Prs	3	expl	3:expl	Discourse=attribution:47->48|Entity=(abstract-18)
2	was	be	AUX	VBD	Mood=Ind|Number=Plur|Person=3|Tense=Past|VerbForm=Fin	3	aux:pass	3:aux:pass	_
3	found	find	VERB	VBN	Tense=Past|VerbForm=Part|Voice=Pass	0	root	0:root	_
4	that	that	SCONJ	IN	_	18	mark	18:mark	Discourse=joint:48->17
5	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	Entity=(abstract-49
6	most	most	ADV	RBS	Degree=Sup	7	advmod	7:advmod	_
7	prominent	prominent	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
8	dasatinib-targeted	dasatinib-targeted	PROPN	NNP	Number=Sing	9	compound	9:compound	Entity=(abstract-90)
9	SFKs	SFK	NOUN	NNS	Number=Plur	18	nsubj	18:nsubj|25:nsubj	Entity=abstract-49)
10	are	be	AUX	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	18	cop	18:cop	_
11	Lyn	Lyn	PROPN	NNP	Number=Sing	18	compound	18:compound	Entity=(abstract-49(abstract-49(person-80)|SpaceAfter=No
12	,	,	PUNCT	,	_	13	punct	13:punct	_
13	Fyn	Fyn	PROPN	NNP	Number=Sing	11	conj	11:conj:and|18:compound	Entity=(abstract-81)|SpaceAfter=No
14	,	,	PUNCT	,	_	16	punct	16:punct	_
15	and	and	CCONJ	CC	_	16	cc	16:cc	_
16	Src	Src	PROPN	NNP	Number=Sing	11	conj	11:conj:and|18:compound	Entity=(abstract-82)|SpaceAfter=No
17	,	,	PUNCT	,	_	16	punct	16:punct	_
18	kinases	kinase	NOUN	NNS	Number=Plur	3	csubj:pass	3:csubj:pass	Entity=abstract-49)
19	and	and	CCONJ	CC	_	18	cc	18:cc	_
20	their	their	PRON	PRP$	Number=Plur|Person=3|Poss=Yes|PronType=Prs	22	nmod:poss	22:nmod:poss	Entity=(abstract-3(substance-91(abstract-49)
21	negative	negative	ADJ	JJ	Degree=Pos	22	amod	22:amod	_
22	regulator	regulator	NOUN	NN	Number=Sing	25	compound	25:compound	Entity=substance-91)
23	C-terminal	C-terminal	PROPN	NNP	Number=Sing	25	compound	25:compound	Entity=(place-92)
24	Src	Src	PROPN	NNP	Number=Sing	25	compound	25:compound	Entity=(abstract-82)
25	kinase	kinase	NOUN	NN	Number=Sing	18	conj	3:csubj:pass|18:conj	Entity=abstract-49)abstract-3)
26	(	(	PUNCT	-LRB-	_	27	punct	27:punct	Discourse=elaboration:49->48|SpaceAfter=No
27	Csk	Csk	PROPN	NNP	Number=Sing	25	appos	25:appos	Entity=(abstract-3)|SpaceAfter=No
28	)	)	PUNCT	-RRB-	_	27	punct	27:punct	SpaceAfter=No
29	,	,	PUNCT	,	_	34	punct	34:punct	_
30	but	but	CCONJ	CC	_	34	cc	34:cc	Discourse=same_unit:50->48
31	nilotinib	nilotinib	NOUN	NN	Number=Sing	34	nsubj	34:nsubj	Entity=(substance-19)
32	does	do	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	34	aux	34:aux	_
33	not	not	ADV	RB	Polarity=Neg	34	advmod	34:advmod	_
34	bind	bind	VERB	VB	VerbForm=Inf	3	conj	3:conj:but	Entity=(event-41)
35	to	to	ADP	IN	_	37	case	37:case	_
36	these	this	DET	DT	Number=Plur|PronType=Dem	37	det	37:det	Entity=(abstract-49
37	kinases	kinase	NOUN	NNS	Number=Plur	34	obl	34:obl:to	Entity=abstract-49)|SpaceAfter=No
38	.	.	PUNCT	.	_	3	punct	3:punct	_

# sent_id = AMALGUM_academic_dasatinib-25
# s_type = decl
# text = During vascular injury it is primarily the subendothelial collagen that activates platelets and result in subsequent platelet aggregation.
1	During	during	ADP	IN	_	3	case	3:case	Discourse=elaboration:51->48
2	vascular	vascular	ADJ	JJ	Degree=Pos	3	amod	3:amod	Entity=(event-75
3	injury	injury	NOUN	NN	Number=Sing	9	nmod	9:nmod:during	Entity=event-75)
4	it	it	PRON	PRP	Case=Nom|Gender=Neut|Number=Sing|Person=3|PronType=Prs	9	nsubj	9:nsubj	Entity=(substance-19)
5	is	be	AUX	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	9	cop	9:cop	_
6	primarily	primarily	ADV	RB	Degree=Pos	9	advmod	9:advmod	Entity=(substance-19
7	the	the	DET	DT	Definite=Def|PronType=Art	9	det	9:det	_
8	subendothelial	subendothelial	ADJ	JJ	Degree=Pos	9	amod	9:amod	_
9	collagen	collagen	NOUN	NN	Number=Sing	0	root	0:root|11:nsubj	_
10	that	that	PRON	WDT	PronType=Rel	11	nsubj	9:ref	Discourse=elaboration:52->51
11	activates	activate	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	9	acl:relcl	9:acl:relcl	_
12	platelets	platelet	NOUN	NNS	Number=Plur	11	obj	11:obj	Entity=(substance-74)
13	and	and	CCONJ	CC	_	14	cc	14:cc	Discourse=joint:53->51
14	result	result	VERB	VBP	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	11	conj	9:acl:relcl|11:conj:and	Entity=substance-19)
15	in	in	ADP	IN	_	18	case	18:case	_
16	subsequent	subsequent	ADJ	JJ	Degree=Pos	18	amod	18:amod	Entity=(abstract-64
17	platelet	platelet	NOUN	NN	Number=Sing	18	compound	18:compound	Entity=(object-40)
18	aggregation	aggregation	NOUN	NN	Number=Sing	14	obl	14:obl:in	Entity=abstract-64)|SpaceAfter=No
19	.	.	PUNCT	.	_	9	punct	9:punct	_

# sent_id = AMALGUM_academic_dasatinib-26
# s_type = decl
# text = A population of the collagen-adhered platelets responds by surface exposure of the procoagulant phosphatidylserine (PS).
1	A	a	DET	DT	Definite=Ind|PronType=Art	2	det	2:det	Discourse=elaboration:54->51|Entity=(animal-93
2	population	population	NOUN	NN	Number=Sing	7	nsubj	7:nsubj	_
3	of	of	ADP	IN	_	6	case	6:case	_
4	the	the	DET	DT	Definite=Def|PronType=Art	6	det	6:det	Entity=(substance-74
5	collagen-adhered	collagen-adhered	ADJ	JJ	Degree=Pos	6	amod	6:amod	_
6	platelets	platelet	NOUN	NNS	Number=Plur	2	nmod	2:nmod:of	Entity=animal-93)substance-74)
7	responds	respond	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
8	by	by	ADP	IN	_	10	case	10:case	Discourse=means:55->54
9	surface	surface	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(event-94(place-95)
10	exposure	exposure	NOUN	NN	Number=Sing	7	obl	7:obl:by	_
11	of	of	ADP	IN	_	14	case	14:case	_
12	the	the	DET	DT	Definite=Def|PronType=Art	14	det	14:det	Entity=(substance-96
13	procoagulant	procoagulant	ADJ	JJ	Degree=Pos	14	amod	14:amod	_
14	phosphatidylserine	phosphatidylserine	NOUN	NN	Number=Sing	10	nmod	10:nmod:of	Entity=event-94)substance-96)
15	(	(	PUNCT	-LRB-	_	16	punct	16:punct	Discourse=restatement:56->55|SpaceAfter=No
16	PS	PS	PROPN	NNP	Number=Sing	14	appos	14:appos	Entity=(abstract-97)|SpaceAfter=No
17	)	)	PUNCT	-RRB-	_	16	punct	16:punct	SpaceAfter=No
18	.	.	PUNCT	.	_	7	punct	7:punct	_

# sent_id = AMALGUM_academic_dasatinib-27
# s_type = decl
# text = This surface expressed PS facilitates the binding of coagulation factors and by this promotes thrombin generation.
1	This	this	DET	DT	Number=Sing|PronType=Dem	4	det	4:det	Discourse=joint:57->17|Entity=(abstract-97
2	surface	surface	NOUN	NN	Number=Sing	3	compound	3:compound	Entity=(place-95)
3	expressed	express	VERB	VBD	Mood=Ind|Number=Sing|Person=3|Tense=Past|VerbForm=Fin	4	amod	4:amod	_
4	PS	PS	PROPN	NNP	Number=Sing	5	nsubj	5:nsubj|14:nsubj	Entity=abstract-97)
5	facilitates	facilitate	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
6	the	the	DET	DT	Definite=Def|PronType=Art	7	det	7:det	Entity=(event-41
7	binding	binding	NOUN	NN	Number=Sing	5	obj	5:obj	_
8	of	of	ADP	IN	_	10	case	10:case	_
9	coagulation	coagulation	NOUN	NN	Number=Sing	10	compound	10:compound	Entity=(abstract-98(abstract-99)
10	factors	factor	NOUN	NNS	Number=Plur	7	nmod	7:nmod:of	Entity=event-41)abstract-98)
11	and	and	CCONJ	CC	_	14	cc	14:cc	Discourse=elaboration:58->57
12	by	by	ADP	IN	_	13	case	13:case	_
13	this	this	PRON	DT	Number=Sing|PronType=Dem	14	obl	14:obl:by	_
14	promotes	promote	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	5	conj	5:conj:and	_
15	thrombin	thrombin	NOUN	NN	Number=Sing	16	compound	16:compound	Entity=(abstract-58(place-100)
16	generation	generation	NOUN	NN	Number=Sing	14	obj	14:obj	Entity=abstract-58)|SpaceAfter=No
17	.	.	PUNCT	.	_	5	punct	5:punct	_

# sent_id = AMALGUM_academic_dasatinib-28
# s_type = decl
# text = In addition, platelets participate in fibrin formation and regulate the process of clot retraction.
1	In	in	ADP	IN	_	2	case	2:case	Discourse=joint:59->17
2	addition	addition	NOUN	NN	Number=Sing	5	obl	5:obl:in	SpaceAfter=No
3	,	,	PUNCT	,	_	2	punct	2:punct	_
4	platelets	platelet	NOUN	NNS	Number=Plur	5	nsubj	5:nsubj|10:nsubj	Entity=(substance-74)
5	participate	participate	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	0	root	0:root	_
6	in	in	ADP	IN	_	8	case	8:case	_
7	fibrin	fibrin	NOUN	NN	Number=Sing	8	compound	8:compound	Entity=(event-101(person-102)
8	formation	formation	NOUN	NN	Number=Sing	5	obl	5:obl:in	Entity=event-101)
9	and	and	CCONJ	CC	_	10	cc	10:cc	Discourse=joint:60->17
10	regulate	regulate	VERB	VBP	Mood=Ind|Number=Plur|Person=3|Tense=Pres|VerbForm=Fin	5	conj	5:conj:and	_
11	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(event-103
12	process	process	NOUN	NN	Number=Sing	10	obj	10:obj	_
13	of	of	ADP	IN	_	15	case	15:case	_
14	clot	clot	NOUN	NN	Number=Sing	15	compound	15:compound	Entity=(event-104(object-105)
15	retraction	retraction	NOUN	NN	Number=Sing	12	nmod	12:nmod:of	Entity=event-103)event-104)|SpaceAfter=No
16	.	.	PUNCT	.	_	5	punct	5:punct	_

# sent_id = AMALGUM_academic_dasatinib-29
# s_type = decl
# text = We intended to investigate whether dasatinib also affects the platelet procoagulant activity and thereby coagulation.
# newpar = p (3 s)
1	We	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	2	nsubj	2:nsubj|4:nsubj:xsubj	Discourse=attribution:61->62|Entity=(person-65)
2	intended	intend	VERB	VBD	Mood=Ind|Number=Plur|Person=1|Tense=Past|VerbForm=Fin	0	root	0:root	_
3	to	to	PART	TO	_	4	mark	4:mark	_
4	investigate	investigate	VERB	VB	VerbForm=Inf	2	xcomp	2:xcomp	_
5	whether	whether	SCONJ	IN	_	8	mark	8:mark	Discourse=joint:62->17
6	dasatinib	dasatinib	NOUN	NN	Number=Sing	8	nsubj	8:nsubj	Entity=(substance-20)
7	also	also	ADV	RB	_	8	advmod	8:advmod	_
8	affects	affect	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	4	ccomp	4:ccomp	_
9	the	the	DET	DT	Definite=Def|PronType=Art	12	det	12:det	Entity=(abstract-106
10	platelet	platelet	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(object-40)
11	procoagulant	procoagulant	NOUN	NN	Number=Sing	12	compound	12:compound	Entity=(person-107)
12	activity	activity	NOUN	NN	Number=Sing	8	obj	8:obj	Entity=abstract-106)
13	and	and	CCONJ	CC	_	15	cc	15:cc	_
14	thereby	thereby	ADV	RB	Degree=Pos	15	advmod	15:advmod	Entity=(abstract-99
15	coagulation	coagulation	NOUN	NN	Number=Sing	12	conj	8:obj|12:conj:and	Entity=abstract-99)|SpaceAfter=No
16	.	.	PUNCT	.	_	2	punct	2:punct	_

# sent_id = AMALGUM_academic_dasatinib-30
# s_type = decl
# text = For this reason, we examined the in vitro and ex vivo effects of dasatinib on platelet procoagulant response in dasatinib treated platelets of healthy volunteers and in samples derived from CML patients on dasatinib therapy.
1	For	for	ADP	IN	_	3	case	3:case	Discourse=joint:63->17
2	this	this	DET	DT	Number=Sing|PronType=Dem	3	det	3:det	Entity=(abstract-108
3	reason	reason	NOUN	NN	Number=Sing	6	obl	6:obl:for	Entity=abstract-108)|SpaceAfter=No
4	,	,	PUNCT	,	_	3	punct	3:punct	_
5	we	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	6	nsubj	6:nsubj	Entity=(person-65)
6	examined	examine	VERB	VBD	Mood=Ind|Number=Plur|Person=1|Tense=Past|VerbForm=Fin	0	root	0:root	_
7	the	the	DET	DT	Definite=Def|PronType=Art	13	det	13:det	Entity=(abstract-109
8	in	in	NOUN	NN	Number=Sing	9	obl:npmod	9:obl:npmod	_
9	vitro	vitro	NOUN	NN	Number=Sing	13	compound	13:compound	Entity=(abstract-62)
10	and	and	CCONJ	CC	_	12	cc	12:cc	_
11	ex	ex	NOUN	NN	Number=Sing	12	obl:npmod	12:obl:npmod	_
12	vivo	vivo	NOUN	NN	Number=Sing	9	conj	9:conj:and|13:compound	_
13	effects	effect	NOUN	NNS	Number=Plur	6	obj	6:obj	_
14	of	of	ADP	IN	_	15	case	15:case	_
15	dasatinib	dasatinib	NOUN	NN	Number=Sing	13	nmod	13:nmod:of	Entity=(substance-20)
16	on	on	ADP	IN	_	19	case	19:case	_
17	platelet	platelet	NOUN	NN	Number=Sing	19	compound	19:compound	Entity=(event-73(object-40)
18	procoagulant	procoagulant	NOUN	NN	Number=Sing	19	compound	19:compound	Entity=(person-107)
19	response	response	NOUN	NN	Number=Sing	13	nmod	13:nmod:on	_
20	in	in	ADP	IN	_	23	case	23:case	_
21	dasatinib	dasatinib	NOUN	NN	Number=Sing	22	compound	22:compound	Entity=(substance-74(substance-20)
22	treated	treat	VERB	VBN	Tense=Past|VerbForm=Part	23	amod	23:amod	_
23	platelets	platelet	NOUN	NNS	Number=Plur	19	nmod	19:nmod:in	_
24	of	of	ADP	IN	_	26	case	26:case	_
25	healthy	healthy	ADJ	JJ	Degree=Pos	26	amod	26:amod	Entity=(animal-110
26	volunteers	volunteer	NOUN	NNS	Number=Plur	23	nmod	23:nmod:of	Entity=abstract-109)event-73)substance-74)animal-110)
27	and	and	CCONJ	CC	_	29	cc	29:cc	_
28	in	in	ADP	IN	_	29	case	29:case	_
29	samples	sample	NOUN	NNS	Number=Plur	20	conj	20:conj:and|23:case	Entity=(object-111
30	derived	derive	VERB	VBN	Tense=Past|VerbForm=Part	29	acl	29:acl	Discourse=elaboration:64->63
31	from	from	ADP	IN	_	33	case	33:case	_
32	CML	CML	PROPN	NNP	Number=Sing	33	compound	33:compound	Entity=(person-112(abstract-26)
33	patients	patient	NOUN	NNS	Number=Plur	30	obl	30:obl:from	_
34	on	on	ADP	IN	_	36	case	36:case	_
35	dasatinib	dasatinib	NOUN	NN	Number=Sing	36	compound	36:compound	Entity=(abstract-113(substance-20)
36	therapy	therapy	NOUN	NN	Number=Sing	33	nmod	33:nmod:on	Entity=object-111)person-112)abstract-113)|SpaceAfter=No
37	.	.	PUNCT	.	_	6	punct	6:punct	_

# sent_id = AMALGUM_academic_dasatinib-31
# s_type = decl
# text = We found that at therapeutic concentration dasatainib, but not nilotinib, has a strong inhibitory effect on platelet procoagulant activity and on clot retraction both in non activated as well as in convulxin activated platelets.
1	We	we	PRON	PRP	Case=Nom|Number=Plur|Person=1|PronType=Prs	2	nsubj	2:nsubj	Discourse=attribution:65->66|Entity=(person-65)
2	found	find	VERB	VBD	Mood=Ind|Number=Plur|Person=1|Tense=Past|VerbForm=Fin	0	root	0:root	_
3	that	that	SCONJ	IN	_	13	mark	13:mark	Discourse=joint:66->17
4	at	at	ADP	IN	_	6	case	6:case	_
5	therapeutic	therapeutic	ADJ	JJ	Degree=Pos	6	amod	6:amod	Entity=(abstract-114
6	concentration	concentration	NOUN	NN	Number=Sing	13	obl	13:obl:at	Entity=abstract-114)
7	dasatainib	dasatainib	NOUN	NN	Number=Sing	13	nsubj	13:nsubj	Entity=(abstract-115)|SpaceAfter=No
8	,	,	PUNCT	,	_	11	punct	11:punct	_
9	but	but	CCONJ	CC	_	11	cc	11:cc	_
10	not	not	ADV	RB	Polarity=Neg	11	advmod	11:advmod	_
11	nilotinib	nilotinib	ADJ	JJ	Degree=Pos	7	conj	7:conj:but|13:nsubj	SpaceAfter=No
12	,	,	PUNCT	,	_	7	punct	7:punct	_
13	has	have	VERB	VBZ	Mood=Ind|Number=Sing|Person=3|Tense=Pres|VerbForm=Fin	2	ccomp	2:ccomp	_
14	a	a	DET	DT	Definite=Ind|PronType=Art	17	det	17:det	Entity=(abstract-47
15	strong	strong	ADJ	JJ	Degree=Pos	17	amod	17:amod	_
16	inhibitory	inhibitory	ADJ	JJ	Degree=Pos	17	amod	17:amod	_
17	effect	effect	NOUN	NN	Number=Sing	13	obj	13:obj	_
18	on	on	ADP	IN	_	21	case	21:case	_
19	platelet	platelet	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=(abstract-106(object-40)
20	procoagulant	procoagulant	NOUN	NN	Number=Sing	21	compound	21:compound	Entity=(person-107)
21	activity	activity	NOUN	NN	Number=Sing	17	nmod	17:nmod:on	Entity=abstract-47)abstract-106)
22	and	and	CCONJ	CC	_	25	cc	25:cc	_
23	on	on	ADP	IN	_	25	case	25:case	_
24	clot	clot	NOUN	NN	Number=Sing	25	compound	25:compound	Entity=(event-104(object-105)
25	retraction	retraction	NOUN	NN	Number=Sing	18	conj	18:conj:and|21:case	_
26	both	both	CCONJ	CC	_	29	cc:preconj	29:cc:preconj	_
27	in	in	ADP	IN	_	29	case	29:case	_
28	non	non	NOUN	NN	Number=Sing	29	obl:npmod	29:obl:npmod	_
29	activated	activate	VERB	VBN	Tense=Past|VerbForm=Part	25	amod	25:amod	Entity=event-104)
30	as	as	ADV	RB	_	36	cc	36:cc	_
31	well	well	ADV	RB	Degree=Pos	30	fixed	30:fixed	_
32	as	as	ADP	IN	_	30	fixed	30:fixed	_
33	in	in	ADP	IN	_	30	fixed	30:fixed	_
34	convulxin	convulxin	NOUN	NN	Number=Sing	35	compound	35:compound	Entity=(substance-74(person-116)
35	activated	activate	VERB	VBN	Tense=Past|VerbForm=Part	36	amod	36:amod	_
36	platelets	platelet	NOUN	NNS	Number=Plur	27	conj	27:conj:as_well_as|29:case	Entity=substance-74)|SpaceAfter=No
37	.	.	PUNCT	.	_	2	punct	2:punct	_

